Nuclear Medicine

PET-CT is one of the world's most advanced molecular imaging devices, capable of completing a full-body scan in a single session. It holds significant importance in the differential diagnosis of neurodegenerative diseases (such as dementia and Parkinson's disease), as well as in the early diagnosis, staging, prognosis assessment, and treatment guidance of benign and malignant tumors. Therefore, PET/CT is widely recognized as the "beacon that illuminates tumors," particularly suitable for tumor screening in high-risk populations and health check-ups for high-end clientele.

SPECT-CT plays a crucial role in assessing myocardial and cerebral blood flow, renal dynamic function tests, early diagnosis of whole-body bone metastases, thyroid morphology and function examinations, and localization diagnosis of lymphatic obstruction. The equipment features three core functions: automatic target delineation, one-click efficacy assessment, and a one-click rapid, precise, and minimally invasive diagnosis and treatment system, which is expected to provide more important evidence for treatment decision-making and efficacy evaluation.

Radionuclide therapy is the most important clinical aspect of nuclear medicine. Among these, Iodine-131 therapy for hyperthyroidism is the most classic and successful clinical application of targeted therapy, offering definitive efficacy, simplicity, and safety, with a single-dose cure rate exceeding 70%. Professor Liang Hong has been engaged in Iodine-131 therapy for hyperthyroidism and thyroid cancer for over 30 years, treating nearly 30,000 cases, and possesses extensive clinical experience.